amira webinar

16
Cancer Metabolism Reinvention of Hallmark of Cancer Miroslava Cuperlovic-Culf, Ph.D. Senior Research Officer, National Research Council of Canada Adjunct Professor, Mount Allison University from Moncton, NB, Canada 22. May, 2012

Upload: fhccommunity

Post on 24-May-2015

320 views

Category:

Business


3 download

DESCRIPTION

Miroslava Cuperlovic-Culf is a Research Officer with National Research Council of Canada and Adjunct Professor of Chemistry at Mount Allison University and University of New Brunswick as well as Adjunct Researcher at Atlantic Cancer Research Institute in Moncton Canada. Miroslava has worked for number of years in the application of metabolomics and transcriptomics in life sciences. She has been actively involved in the bioinformatics, computational biology and computational chemistry however she has also extensive experience and training in experimental methodologies for high throughput analysis of biological systems. Her primary interest is in the exploitation of metabolic changes in cancer for treatment and diagnostics. Miroslava authored many articles, book chapters and several patents as well as the book entitled NMR Metabolomics in Cancer Research. She lives and works in Moncton, New Brunswick, Canada. In this webinar, Dr. Miroslava’s will talk about cancer metabolic phenotype, analysis of metabolism in cancers and the research work with her collaborators on the investigation of metabolic changes in cancer subtypes.The session will be moderated by Dr. Amira Djebbari. Dr. Djebbari trained at The Institute for Genomic Research. She completed her post-doctoral experience at the Dana Farber Cancer Institute and Harvard School of Public Health. Dr. Djebbari is currently a scientific project manager in the Ontario Cancer Institute, Princess Margaret Hospital at the University of Toronto.

TRANSCRIPT

Page 1: Amira   webinar

Cancer Metabolism Reinvention of Hallmark of Cancer

Miroslava Cuperlovic-Culf, Ph.D.

Senior Research Officer, National Research Council of Canada

Adjunct Professor, Mount Allison University

from Moncton, NB, Canada

22. May, 2012

Page 2: Amira   webinar

TissueCancer analysisDiagnosticPrognostic Organism

Treatment assessmentDiagnosticRisk assesment

Cell

Cancer analysisDrug discoveryDiagnostic

ALTERED METABOLISM:CAUSE or EFFECT OF CANCER

Page 3: Amira   webinar

Genetic changes of oncogenes andOncosuppressors

Cancer metabolic phenotype

Tumour microenvironment(pH, hypoxia, nutrient deprivation, autophagy)

Bioenergetics

Biosynthesis

Oxidative state

Page 4: Amira   webinar

Glucose

Glucose

PEP

Pyruvate

G6P

Lactate + H+

Lactate +H+

R5P

AcetylCoA

Citrate

aKG

Amino Acids Import

Citrate

Acetyl CoA

Fatty acids

Glutamate

H2CO3

H++ CO2

GLUT1

ATP

ADPGLY

COLY

SIS

Cholesterol

PPP

CANCER METABOLIC PHENOTYPE

FATT

Y AC

IDSY

NTH

ESIS

NUCLEOTIDESSYNTHESIS

AMINO ACIDSYNTHESIS

Fatty acids

Page 5: Amira   webinar
Page 6: Amira   webinar
Page 7: Amira   webinar

MYCHIF1

AKTp53

STAT3

EGFR

Page 8: Amira   webinar

SNPAlternative splicingTranscription factorsEpigenetics

miRNA;Translation kinetics

AbilityDesire

Strategy

Action

Protein activation/inhibitionProtein interactions

Cuperlovic-Culf, et al. Exp Opin Mol Diagn 2008; Cuperlovic-Culf, et al. DDT 2010; Cuperlovic-Culf, NMR Metabolomics in Cancer Research. Oxford Biosciences, 2013

Page 9: Amira   webinar

LN229

BS149

LN319

LN18

A172

U343

LN405

U373

HS683

Cuperlovic-Culf, et al. Jour Biol Chem 2012

Glioblastoma multiforme the most common and most aggressive malignant primary brain tumor in humans: median survival 3months – 2 years (with treatment)

Page 10: Amira   webinar
Page 11: Amira   webinar

1 2 3 4

SAM method: Tusher, et al. PNAS, 2001

Page 12: Amira   webinar

Microarray data from: Grzmil, et al. Cancer Res, 2001, GSE15824 Wiedemeyer, et al. Cancer Cell 2008, GSE9200

overexpression in group Increased metabolites

Group 1:overexpression (red) Increased metabolites

Page 13: Amira   webinar

CONCLUSIONS• Metabolic profiling (qualitative and

quantitative) leads to information about tumour subtypes;

• Metabolic biomarkers for tumour subtypes can be related to gene expression characteristics;

FUTURE

Page 14: Amira   webinar

CONCLUSIONS FUTURE• Testing of clinical samples for

biomarkers of subtypes discovery and validation;

• Development and testing of drug options for glioblastoma subtypes

Page 15: Amira   webinar

THANK YOU/ MERCI

Mohamed TouaibiaPier Jr. Morin

David FergusonMarc Surette

Anissa Belkaid

Rodney OuelletteAdrian CulfNatalie Lefort

Nabil BelacelDan TulpanJason Hines

Page 16: Amira   webinar

METABOLITE CANCER NORMALL-Valine

L-LeucineL-Isoleucine

73.01(1.36) 110.53(9.12)

L-Lysine 10.31(1.36) 20.55(2.21)L-Alanine 11.62(1.54) 16.35(1.1)

L-Aspartic acid 0.77(0.08) 2.65(0.71)Phenylalanine 6.06(0.96) 11.12(1.88)

Tyrosine 0.25(0.12) 0.50(0.14)Glutamine 5.53(0.83) 3.44(0.81)

Total Choline 13.93(5.32) 6.58(1.84)UDP-glucose 6.59(0.75) 1.63(1.63)

Lactic acid 58.29(13.84) 56.47(18.19)

METABOLITE IDC (ER+) AC (ER-)L-Valine

L-LeucineL-Isoleucine

78.05(1.76) 67.98(6.10)

Glycerol-3-phosphate 50.31(4.56) 38.27(2.12)

L-Alanine 12.06(0.59) 11.17(2.05)

L-Aspartic acid 0.79(0.07) 0.74(0.09)Phenylalanine 6.82(0.62) 5.23(0.51)

Tyrosine 0.26(0.08) 0.24(0.16)Choline 15.02(5.01) 12.84(5.66)

Lactic acid 49.2(3.19) 67.39(14.51)

Cuperlovic-Culf, et al. Chem Sci (2011)

BREAST CANCER